

Dear Author,

Here are the proofs of your article.

- You can submit your corrections **online**, via **e-mail** or by **fax**.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- You can also insert your corrections in the proof PDF and **email** the annotated PDF.
- For fax submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the **journal title**, **article number**, and **your name** when sending your response via e-mail or fax.
- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- **Check** the questions that may have arisen during copy editing and insert your answers/ corrections.
- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style. Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- If we do not receive your corrections **within 48 hours**, we will send you a reminder.
- Your article will be published **Online First** approximately one week after receipt of your corrected proofs. This is the **official first publication** citable with the DOI. **Further changes are, therefore, not possible.**
- The **printed version** will follow in a forthcoming issue.

Please note

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL: [http://dx.doi.org/\[DOI\]](http://dx.doi.org/[DOI]).

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information go to: <http://www.springerlink.com>.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us if you would like to have these documents returned.

Metadata of the article that will be visualized in OnlineFirst

ArticleTitle	Tuberculosis as a risk factor for systemic lupus erythematosus: results of a nationwide study in Taiwan	
Article Sub-Title		
Article CopyRight	Springer-Verlag (This will be the copyright line in the final PDF)	
Journal Name	Rheumatology International	
Corresponding Author	Family Name	Sung
	Particle	
	Given Name	Fung-Chang
	Suffix	
	Division	
	Organization	Management Office for Health Data, China Medical University Hospital
	Address	Taichung, Taiwan
	Division	Institute of Environmental Health, College of Public Health
	Organization	China Medical University
	Address	91 Hsueh-Shih Road 16F, Taichung, 404, Taiwan
	Email	fcsung@mail.cmu.edu.tw
Corresponding Author	Family Name	Chen
	Particle	
	Given Name	Wei
	Suffix	
	Division	Division of Pulmonary and Critical Care Medicine, Chia-Yi Christian Hospital
	Organization	China Medical University
	Address	Chia-Yi, 600, Taiwan
	Division	Department of Life Sciences
	Organization	National Chung Hsing University
	Address	Taichung, Taiwan
	Division	Department of Respiratory Therapy
	Organization	China Medical University
	Address	Taichung, 404, Taiwan
	Email	peteralfa2004@yahoo.com.tw
Author	Family Name	Lin
	Particle	
	Given Name	Yu-Chao
	Suffix	
	Division	Division of Pulmonary and Critical Care Medicine
	Organization	China Medical University Hospital
	Address	Taichung, Taiwan
	Email	
Author	Family Name	Liang
	Particle	
	Given Name	Shinn-Jye
	Suffix	

	Division	Division of Pulmonary and Critical Care Medicine
	Organization	China Medical University Hospital
	Address	Taichung, Taiwan
	Email	
Author	Family Name	Liu
	Particle	
	Given Name	Yi-Heng
	Suffix	
	Division	Division of Pulmonary and Critical Care Medicine
	Organization	China Medical University Hospital
	Address	Taichung, Taiwan
	Email	
Author	Family Name	Hsu
	Particle	
	Given Name	Wu-Huei
	Suffix	
	Division	Division of Pulmonary and Critical Care Medicine
	Organization	China Medical University Hospital
	Address	Taichung, Taiwan
	Email	
Author	Family Name	Shih
	Particle	
	Given Name	Chuen-Ming
	Suffix	
	Division	Division of Pulmonary and Critical Care Medicine
	Organization	China Medical University Hospital
	Address	Taichung, Taiwan
	Email	
Schedule	Received	22 October 2010
	Revised	
	Accepted	18 February 2011
Abstract	<p>A previous study, with relatively small number of patients, showed that prior <i>Mycobacterium tuberculosis</i> (TB) may precipitate SLE in patients from endemic areas. The purpose of the study was to investigate the relationship between prior TB infection and systemic lupus erythematosus (SLE) from the National Health Insurance Research Database (NHIRD) in Taiwan. Cases of SLE and TB were identified from the NHIRD with corresponding ICD-9 codes 710.0 and 011-018, respectively, from January 2000 to December 2008. A total of 2,721 cases of SLE and 10,823 control subjects were included in data analysis. The average annual incidence rate was 8.1 per 100,000. The annual incidence rates of SLE decreased from 6.38 per 100,000 to 2.55 per 100,000 during 2000–2008. Compared with the control subjects, SLE patients were more likely to be white collar workers ($P=0.0005$), reside in highly urbanized areas ($P=0.0140$), and have higher incomes ($P=0.0088$). TB was much more prevalent in SLE patients than in the control subjects (1.8 vs. 0.9%, $P<0.001$). The mean time interval between diagnosis of TB and SLE was 45.58 ± 39.0 months. On multivariate analysis, TB was the greatest potential risk factor for precipitating SLE (OR = 2.11, 95% CI = 1.49–3.00). In addition, patients with co-existing TB and DM had a higher risk of SLE than the control group (OR = 3.91, 95% CI 1.84–8.31). In conclusion, this study suggests that there is an increased risk of precipitating SLE among patients with TB in Taiwan from a nationwide health insurance research dataset. Mycobacterial infections could trigger autoimmune diseases in experimental studies. Furthermore, a study with relatively small number of patients revealed that prior TB may precipitate SLE in patients from endemic</p>	

areas. There is an increased risk of precipitating SLE among patients with TB in Taiwan from a nationwide health insurance research dataset during a 9-year period.

Keywords (separated by '-') Systemic lupus erythematosus - Tuberculosis - Risk factor - Health insurance

Footnote Information Y.-C. Lin and S.-J. Liang contributed equally.

Journal: 296
Article: 1847



Author Query Form

**Please ensure you fill out your response to the queries raised below
and return this form along with your corrections**

Dear Author

During the process of typesetting your article, the following queries have arisen. Please check your typeset proof carefully against the queries listed below and mark the necessary changes either directly on the proof/online grid or in the 'Author's response' area provided below

Query	Details required	Author's response
1.	Please check and confirm if the corresponding authors' affiliation is correctly identified, and also check if authors' respective affiliation is correctly given	
2.	The reference citation "Kanjaksha et al. [13]" does not match with the list. Please check and change accordingly.	
3.	Kindly check conflict of interest.	
4.	Please check and confirm if the inserted year is correct in Refs. [1, 2, 4, 18]	
5.	Please check and confirm if the inserted doi is correct in Ref. [3]	

2 Tuberculosis as a risk factor for systemic lupus erythematosus: 3 results of a nationwide study in Taiwan

4 Yu-Chao Lin · Shinn-Jye Liang · Yi-Heng Liu ·
5 Wu-Huei Hsu · Chuen-Ming Shih ·
6 Fung-Chang Sung · Wei Chen

7 Received: 22 October 2010 / Accepted: 18 February 2011
8 © Springer-Verlag 2011

9 **Abstract** A previous study, with relatively small number
10 of patients, showed that prior *Mycobacterium tuberculosis*
11 (TB) may precipitate SLE in patients from endemic areas.
12 The purpose of the study was to investigate the relationship
13 between prior TB infection and systemic lupus erythematosus
14 (SLE) from the National Health Insurance Research
15 Database (NHIRD) in Taiwan. Cases of SLE and TB were
16 identified from the NHIRD with corresponding ICD-9
17 codes 710.0 and 011-018, respectively, from January 2000

to December 2008. A total of 2,721 cases of SLE and 18
10,823 control subjects were included in data analysis. The 19
average annual incidence rate was 8.1 per 100,000. The 20
annual incidence rates of SLE decreased from 6.38 per 21
100,000 to 2.55 per 100,000 during 2000–2008. Compared 22
with the control subjects, SLE patients were more likely to 23
be white collar workers ($P = 0.0005$), reside in highly 24
urbanized areas ($P = 0.0140$), and have higher incomes 25
($P = 0.0088$). TB was much more prevalent in SLE patients 26
than in the control subjects (1.8 vs. 0.9%, $P < 0.001$). The 27
mean time interval between diagnosis of TB and SLE was 28
 45.58 ± 39.0 months. On multivariate analysis, TB was the 29
greatest potential risk factor for precipitating SLE 30
(OR = 2.11, 95% CI = 1.49–3.00). In addition, patients 31
with co-existing TB and DM had a higher risk of SLE than 32
the control group (OR = 3.91, 95% CI 1.84–8.31). In con- 33
clusion, this study suggests that there is an increased risk of 34
precipitating SLE among patients with TB in Taiwan from 35
a nationwide health insurance research dataset. Mycobacterial 36
infections could trigger autoimmune diseases in experimental 37
studies. Furthermore, a study with relatively small number 38
of patients revealed that prior TB may precipitate SLE in 39
patients from endemic areas. There is an increased risk of 40
precipitating SLE among patients with TB in Taiwan from 41
a nationwide health insurance research dataset during a 42
9-year period. 43

A1 Y.-C. Lin and S.-J. Liang contributed equally.

A2 Y.-C. Lin · S.-J. Liang · Y.-H. Liu · W.-H. Hsu · C.-M. Shih
A3 Division of Pulmonary and Critical Care Medicine,
A4 China Medical University Hospital, Taichung, Taiwan

A5 F.-C. Sung
A6 Management Office for Health Data,
A7 China Medical University Hospital, Taichung, Taiwan

A8 F.-C. Sung (✉)
A9 Institute of Environmental Health, College of Public Health,
A10 China Medical University,
A11 91 Hsueh-Shih Road 16F, Taichung 404, Taiwan
A12 e-mail: fcsung@mail.cmu.edu.tw

A13 W. Chen (✉)
A14 Division of Pulmonary and Critical Care Medicine,
A15 Chia-Yi Christian Hospital, China Medical University,
A16 Chia-Yi 600, Taiwan
A17 e-mail: peteralfa2004@yahoo.com.tw

A18 W. Chen
A19 Department of Life Sciences,
A20 National Chung Hsing University, Taichung, Taiwan

A21 W. Chen
A22 Department of Respiratory Therapy, China Medical University,
A23 Taichung 404, Taiwan

Keywords Systemic lupus erythematosus · 44
Tuberculosis · Risk factor · Health insurance 45

Introduction 46

Systemic lupus erythematosus (SLE), an autoimmune 47
disease with multiple organ involvement, is a highly 48

49	pleiomorphic disease predominantly affecting young	98
50	women of reproductive age [1]. The pathogenesis of SLE is	99
51	still unclear, but it may be related to several factors, such as	100
52	hormones, genetics, environment and virus infection [2].	
53	The hall mark of this disorder is the presence of autoanti-	101
54	bodies to single stranded and double stranded DNA.	
55	<i>Mycobacterial tuberculosis</i> (TB) infection is still a major	102
56	health problem worldwide, both in developed [3] and	103
57	developing countries [4, 5]. It affects almost one-third of	104
58	the global population and is the secondary cause of death	105
59	among infectious diseases [6, 7]. Experimental models of	106
60	autoimmune diseases such as mycobacteria-induced arthritis	107
61	have shown many features of autoimmunity [8, 9], and	108
62	monoclonal antibodies raised against TB can cross react	109
63	with DNA [10]. Thus, it is possible that mycobacterial	110
64	infections could trigger autoimmune diseases.	111
65	Several studies have shown an increased prevalence of	112
66	tuberculosis in SLE patients, both from non-endemic and	113
67	endemic countries [11, 12]. Treatment for SLE leading to	114
68	immunosuppression may be the cause of the high preva-	115
69	lence of TB. However, there are only limited studies on	116
70	whether TB infection precipitates SLE. Kanjaksha et al.	117
71	[13] reported that TB plays a role in precipitating SLE in	118
72	genetically predisposed patients. However, their sample	119
73	size was relatively small.	120
74	TB infection is a common disease in Taiwan, with an	121
75	incidence of 74.6 cases per 100,000 population [14].	122
76	Taiwan initiated a National Health Insurance program in	
77	1995, and the data available from this program offer a	123
78	unique opportunity for research. In the present study, we	
79	used a 9-year nationwide population-based dataset to	
80	determine the risk of SLE among patients with TB.	
81	Methods and materials	
82	Data source	
83	Insurance claim data were obtained from the National	124
84	Health Research Institute in Taiwan (NHRI) with the	125
85	authorization of the Bureau of National Health Insurance,	126
86	Department of Health. The universal National Health	127
87	Insurance (NHI) program was implemented in Taiwan in	128
88	1995. It covers approximately 99% of the total 23 million	129
89	population and includes contracts with 97% of hospitals	130
90	and clinics in Taiwan. The National Health Research Insti-	131
91	tute established and updates the NHI Research Database,	132
92	which contains all claims data from 1996 to 2008. From	133
93	this research database, a dataset was created by randomly	134
94	selecting 1 million insured subjects, including information	135
95	on ambulatory care, inpatient care, dental service, prescription	136
96	drugs, medical institution, physician providing the services	137
97	and the registration file. Personal identification is encrypted	138
	before the release of the dataset for public access. We used	139
	this random dataset in this study with approval from the	140
	National Health Research Institute.	141
	Criteria and definitions	142
	In this population-based nested case-control study, we	143
	identified patients aged more than 18 years with newly	144
	diagnosed systemic lupus erythematosus (SLE, Interna-	
	tional Classification of Disease Diagnoses, Ninth revision	
	[ICD-9-CM] code 710.0) from outpatient claim files or	
	hospitalization records during 2000–2008. Control subjects	
	were aged more than 18 years and were randomly selected	
	from individuals in the database without SLE at a ratio of	
	1:4 (patients vs. controls) during the same time period. In	
	Taiwan, the diagnosis of SLE was confirmed based on the	
	fulfilling of American College of Rheumatology criteria. In	
	addition, in our strict policy, SLE is included in the list of	
	catastrophic illnesses published by the Department of	
	Health, Executive Yuan. The approval of the status of cata-	
	strophic illness is subject to evaluation and review by the	
	Bureau of NHI, and patients with catastrophic illness	
	certificates are eligible for exemption from insurance	
	premiums and co-payments. Therefore, catastrophic illness	
	patient data are highly accurate and reliable. Under this	
	verification, a total of 2,721 cases of SLE and 10,823	
	control subjects were included in the data analysis.	
	TB and comorbidities	
	Study subjects were considered to have history of tuberculosis	
	infection (TB) if they had received medical care at least	
	twice, including outpatient visits and/or hospitalizations,	
	for a principal diagnosis of TB (ICD-9-CM code 011-018)	
	prior to the diagnosis of SLE. In Taiwan, TB diagnosis was	
	confirmed by microbiological analysis and/or histopatholog-	
	ical evaluation. The comorbidities identified in this study	
	were diabetes mellitus (DM, ICD-9-CM code 250), end	
	stage renal disease (ESRD, ICD-9-CM code 585) and liver	
	cirrhosis (ICD-9-CM codes 571.2 and 571.5). To estimate	
	the levels of urbanization where the study subjects	
	registered for NHI, we calculated the population density	
	(persons/km ²) for each of the 319 townships and city	
	districts in Taiwan. The areas with population densities in	
	the first quartile and fourth quartile were classified as areas	
	of low urbanization and high urbanization, respectively.	
	Areas in the remaining two quartiles were categorized as	
	moderate urbanization.	
	Statistical analysis	
	We calculated the annual incidence rates of SLE as the	
	numbers of SLE cases divided by population. The temporal	

145 trend in the occurrence of SLE was examined using the
146 Poisson regression model. We compared the differences in
147 age, sex, occupation, level of urbanization, residential area
148 and monthly income between cases with SLE and control
149 subjects using the Chi-square test. To assess the association
150 between TB and the risk of new occurrence of SLE, we
151 performed multiple logistic regression analyses to estimate
152 odds ratios (ORs) and 95% confidence intervals (CIs) of
153 SLE associated with TB after controlling for age, gender,
154 occupation, levels of urbanization and income. The regression
155 analyses were repeated in patient subgroups stratified by
156 status of DM. All analyses were performed using SAS
157 statistical software (version 9.1 for Windows; SAS
158 Institute, Inc., Cary, NC). The results were considered to be
159 statistically significant when two-tailed *P* values were less
160 than 0.05.

161 Results

162 A total of 2,721 cases of SLE and 10,823 control subjects
163 were included in the data analysis. Among the 2,721 SLE
164 cases, 49 patients (1.8%) were diagnosed with antecedent
165 TB.

166 The annual incidence rates of SLE over the 9-year period
167 are shown in Table 1. The incidence rates of SLE decreased
168 from 6.38 per 100,000 to 2.55 per 100,000 during 2000–
169 2008. Using Poisson regression models, the trends of SLE
170 incidence significantly decreased with increasing year
171 ($P < 0.001$). Compared with the control subjects, SLE
172 patients were more likely to be white collar workers
173 ($P = 0.0005$), reside in highly urbanized areas ($P = 0.0140$),
174 and have higher incomes ($P = 0.0088$) (Table 2). TB was
175 much more prevalent in SLE patients than in the control
176 subjects (1.8 vs. 0.9%, $P < 0.001$). However, SLE patients
177 tended to have a higher prevalence rate of DM (8.5 vs.
178 9.9%, $P = 0.023$).

Table 1 Annual incidence of systemic lupus erythematosus in Taiwan during 2000–2008

Year	Total population	<i>n</i>	Incidence (rate/per 100,000 persons)
2000	954,021	609	6.38
2001	941,337	429	4.56
2002	928,760	373	4.02
2003	918,043	306	3.33
2004	909,689	292	3.21
2005	902,561	291	3.22
2006	894,806	237	2.65
2007	886,904	270	3.04
2008	877,959	224	2.55

Systemic lupus erythematosus = icd9 237 code: 710.0

Table 2 Sociodemographic characteristics and comorbidities of cases with systemic lupus erythematosus and control subjects

	Control subjects (<i>N</i> = 10,823) <i>n</i> (%)	Patients with SLE (<i>N</i> = 2,721) <i>n</i> (%)	<i>P</i> value
Gender			0.8919
Women	8,771 (81.0)	2,202 (80.9)	
Men	2,052 (19.0)	519 (19.1)	
Age (years)			0.4363
18–44	6,534 (60.4)	1,606 (59.0)	
45–64	3,029 (28.0)	789 (29.0)	
≥65	1,260 (11.6)	326 (12.0)	
Occupation			0.0005
White collar	5,979 (55.2)	1,572 (57.8)	
Blue collar	3,481 (32.2)	772 (28.4)	
Others	1,363 (12.6)	377 (13.8)	
Urbanization			0.0140
Low	381 (3.5)	72 (2.6)	
Moderate	2,932 (27.1)	696 (25.6)	
High	7,510 (69.4)	1,952 (71.8)	
Monthly income (NTD)			0.0088
<15,000	4,078 (37.7)	1,024 (37.6)	
15,000–29,999	5,309 (49.0)	1,277 (46.9)	
≥30,000	1,436 (13.3)	420 (15.5)	
TB			<0.0001
No	10,729 (99.1)	2,672 (98.2)	
Yes	94 (0.9)	49 (1.8)	
DM			0.0226
No	9,748 (90.1)	2,490 (91.5)	
Yes	1,075 (9.9)	231 (8.5)	
ESRD			0.5714
No	10,779 (99.6)	2,712 (99.7)	
Yes	44 (0.4)	9 (0.3)	
Liver cirrhosis			0.1778
No	10,816 (99.9)	2,717 (99.8)	
Yes	7 (0.1)	4 (0.2)	

NTD new Taiwan dollar, TB tuberculosis, DM diabetes mellitus, ESRD end stage renal disease

179 Compared with the control subjects, TB patients had a
180 crude OR of 2.09 for SLE (95% CI = 1.48–2.97) (Table 3).
181 The strength of the association between TB and SLE was at
182 the same level after controlling for other potential risk fac-
183 tors (OR = 2.11, 95% CI = 1.49–3.00, model 1). The mean
184 time interval between diagnosis of TB and SLE was
185 45.58 ± 39.0 months.

186 Table 4 presents the association between TB and risk of
187 SLE among patients with and without DM. TB patients
188 were at a higher risk of SLE than the control subjects in the

Table 3 Odds ratios and 95% confidence intervals of systemic lupus erythematosus in relation to tuberculosis infection and other potential risk factors

	Unadjusted OR (95% CI)	Adjusted ^a OR (95% CI)
Gender		
Women	1.00 (reference)	1.00 (reference)
Men	1.01 (0.91–1.12)	0.98 (0.88–1.09)
Age (years)		
18–44	1.00 (reference)	1.00 (reference)
45–64	1.06 (0.96–1.17)	1.08 (0.98–1.19)
≥65	1.05 (0.92–1.20)	1.09 (0.95–1.25)
Occupation		
White collar	1.00 (reference)	1.00 (reference)
Blue collar	0.84 (0.77–0.93)	0.87 (0.78–0.97)
Others	1.05 (0.93–1.20)	1.11 (0.96–1.28)
Urbanization		
Low	1.00 (reference)	1.00 (reference)
Moderate	1.26 (0.96–1.64)	1.26 (0.96–1.64)
High	1.38 (1.06–1.78)	1.33 (1.03–1.73)
Monthly income (NTD)		
<15,000	1.00 (reference)	1.00 (reference)
15,000–29,999	0.96 (0.87–1.05)	1.03 (0.93–1.15)
≥30,000	1.17 (1.02–1.33)	1.18 (1.02–1.36)
Tuberculosis infection		
No	1.00 (reference)	1.00 (reference)
Yes	2.09 (1.48–2.97)	2.11 (1.49–3.00)

NTD new Taiwan dollar

^a Adjusted for all variables listed in table**Table 4** Adjusted odd ratios for systemic lupus erythematosus in relation to tuberculosis infection by status of diabetes

	Diabetes	
	No (<i>N</i> = 12,238)	Yes (<i>N</i> = 1,306)
	OR (95% CI)	OR (95% CI)
Tuberculosis infection		
No	1.00 (reference)	1.00 (reference)
Yes	1.76 (1.18–2.65)	3.91 (1.84–8.31)

OR odds ratio, CI confidence interval

Models were adjusted for gender, age, occupation, levels of urbanization, and monthly income

189 non-DM group (adjusted OR = 1.76, 95% CI = 1.18–2.65).
 190 The association was stronger in the DM group (OR = 3.91,
 191 95% CI = 1.84–8.31).

192 Discussion

193 This is the first nationwide population-based study evaluating
 194 the relationship between TB and SLE in Taiwan. In this

study, there was a significantly higher incidence of preceding
 TB infection among SLE patients (1.8%) than in the
 general population (0.9%, $P < 0.0001$). On multivariate
 analysis, TB was the greatest potential risk factor for
 precipitating SLE (OR = 2.11, 95% CI = 1.49–3.00). We
 suggest, therefore, that prior TB infection may play a role
 in precipitating SLE in an endemic area.

The incidence rate of SLE varies from country to country.
 Naleway et al. [15] showed that the age-adjusted incidence
 rate of SLE was 5.1 per 100,000 in the USA, and Nightingale
 et al. [16] revealed that the nationwide incidence rate
 was 3.0 per 100,000 in the UK. However, there are scant
 recent data on the incidence rates of SLE in adult popula-
 tions in Asia. Iseki et al. [17] demonstrated that the crude
 incidence of SLE in Okinawa from 1972 to 1991 was 0.9 to
 2.9 per 100,000 by hospital and clinical-based studies. In
 the present study, the incidence rate of SLE was around 3–6
 per 100,000 from 2000 to 2008. The incidence decreased
 steadily during the study period from 6.38 per 100,000 in
 2000 to 2.55 per 100,000 in 2008, which is consistent with
 a previous report [18]. The trend of a declining incidence of
 SLE in Taiwan might be related to the health insurance
 system offered by the government since 1995. The health
 insurance system has increased the number of patients
 seeking medical care, hence the incidence increased
 steadily from 1999 to 2002 [19]. Thereafter, the incidence
 rate steadily declined reaching a plateau in the last 6 years.
 However, whether the decline in the incidence of SLE is a
 real effect or an effect of health policy needs further
 investigation.

Case ascertainment in the present study was according to
 clinical coding, which may raise the question of diagnostic
 accuracy. However, the criteria we used for SLE recruit-
 ment has been accepted by several journals [18–20]. In
 addition, diagnosis of TB is quite strict in Taiwan. Once TB
 has been diagnosed using ICD-9 code 011-018, either in
 outpatient clinics or hospitals, the Center for Disease
 Control monitors the patient carefully and regularly.

From the previous study, 20% of SLE patients were
 found to have confirmed antecedent tuberculosis over 2-year
 period. However, in our study, there were only 1.8% of
 SLE patients were found to have prior TB infection. It is
 probably because that the prevalence of tuberculosis is
 higher in India than in Taiwan. The prevalence of tubercu-
 losis in India is 505 per 100,000, and it is 113 per 100,000
 in Taiwan.

Interestingly, we also observed that TB patients were at
 a higher risk of SLE than the control subjects in the non-
 DM group (adjusted OR = 1.76, 95% CI = 1.18–2.65). The
 association was even stronger in the DM group (OR = 3.91,
 95% CI = 1.84–8.31). Whether this relationship truly
 exists, an explanation of the mechanism will need further
 investigations.

248 Regarding the relationship between TB infection and
 249 autoimmunity, several phenomena have been addressed.
 250 First, several autoantibodies can be detected in TB patients,
 251 such as antinuclear antibody [21] and rheumatoid factor
 252 [22]. In addition, anti-TB drugs, such as isoniazid, can
 253 induce autoantibodies and SLE-like syndrome [23, 24].
 254 Second, “molecular mimicry” prevents the autoantibodies
 255 from the mycobacteria reacting with mycobacteria, and
 256 causes them to react with host antigen. Shoenfeld et al. [25]
 257 showed that monoclonal anti-TB antibodies were found to
 258 react with ssDNA, dsDNA and anti-DNA autoantibodies
 259 from SLE patients binding the glycolipids of part of the
 260 mycobacterial cell wall. Third, the clinical expression of
 261 autoimmune diseases may be modified by permissive and
 262 protective environmental factors. One study demonstrated
 263 that TNF polymorphism plays an opposite role of autoim-
 264 munity and tuberculosis in a northwestern Colombian pop-
 265 ulation [26]. Taken together, the above findings suggest
 266 that tuberculosis could be one of the factors that triggers
 267 autoimmunity.

268 In conclusion, this is the first nationwide population-
 269 based study evaluating the relationship between TB and
 270 SLE in Taiwan. We suggest that prior TB infection may
 271 play a role in precipitating SLE in an endemic area.

272 **Acknowledgments** This study was supported by the National
 273 Sciences Council, Executive Yuan (Grant Numbers NSC 95-2625-Z-
 274 039-002, NSC 96-2625-Z-039-003, NSC 97-2625-M-039-003, NSC 98-
 275 2621-M-039-001), China Medical University Hospital (Grant Number
 276 IMS1) and Taiwan Department of Health Clinical Trial and Research
 277 Center for Excellence (Grant Number DOH99-TD-B-111-004).

278 **Conflict of interest** None of the authors have any potential conflicts
 279 of interest.

280 References

- 281 1. Bertsias GK, Salmon JE, Boumpas DT (2010) Therapeutic oppor-
 282 tunities in systemic lupus erythematosus: state of the art and pros-
 283 pects for the new decade. *Ann Rheum Dis* 69:1603–1611
- 284 2. Pavlovic M, Kats A, Cavallo M et al (2010) Clinical and molecular
 285 evidence for association of SLE with parvovirus B19. *Lupus* 19:
 286 783–792
- 287 3. Svensson E, Millet J, Lindqvist A et al (2010) Impact of immigra-
 288 tion on tuberculosis epidemiology in a low burden country. *Clin*
 289 *Microbiol Infect* doi:10.1111/j.1469-0691.2010.03358.x
- 290 4. Furlow B (2010) Tuberculosis: a review and update. *Radiol*
 291 *Technol* 82:33–52
- 292 5. Hehenkamp A, Hargreaves S (2003) Tuberculosis treatment in
 293 complex emergencies: South Sudan. *Lancet* 362(Suppl):s30–s31
- 294 6. Frieden TR, Sterling TR, Munsiff SS et al (2003) Tuberculosis.
 295 *Lancet* 362:887–899

7. Corbett EL, Watt CJ, Walker N et al (2003) The growing burden
 296 of tuberculosis: global trends and interactions with the HIV
 297 epidemic. *Arch Intern Med* 163:1009–1021 298
8. Holoshitz J, Matitiau A, Cohen IR (1984) Arthritis induced in rats
 299 by cloned T lymphocytes responsive to mycobacteria but not to
 300 collagen type II. *J Clin Invest* 73:211–215 301
9. van Eden W, Holoshitz J, Nevo Z et al (1985) Arthritis induced by
 302 a T-lymphocyte clone that responds to *Mycobacterium tuberculosis*
 303 and to cartilage proteoglycans. *Proc Natl Acad Sci USA* 82:5117–
 304 5120 305
10. Shoenfeld Y, Schwartz RS (1984) Immunologic and genetic
 306 factors in autoimmune diseases. *N Engl J Med* 311:1019–1029 307
11. Sayarlioglu M, Inanc M, Kamali S et al (2004) Tuberculosis in
 308 Turkish patients with systemic lupus erythematosus: increased
 309 frequency of extrapulmonary localization. *Lupus* 13:274–278 310
12. Yun JE, Lee SW, Kim TH et al (2002) The incidence and clinical
 311 characteristics of *Mycobacterium tuberculosis* infection among
 312 systemic lupus erythematosus and rheumatoid arthritis patients in
 313 Korea. *Clin Exp Rheumatol* 20:127–132 314
13. Ghosh K, Patwardhan M, Pradhan V (2009) Mycobacterium
 315 tuberculosis infection precipitates SLE in patients from endemic
 316 areas. *Rheumatol Int* 29:1047–1050 317
14. Hsueh PR, Liu YC, So J et al (2006) Mycobacterium tuberculosis
 318 in Taiwan. *J Infect* 52:77–85 319
15. Naleway AL, Davis ME, Greenlee RT et al (2005) Epidemiology
 320 of systemic lupus erythematosus in rural Wisconsin. *Lupus*
 321 14:862–866 322
16. Nightingale AL, Farmer RD, de Vries CS (2006) Incidence of
 323 clinically diagnosed systemic lupus erythematosus 1992–1998
 324 using the UK General Practice Research Database. *Pharmacoepi-*
 325 *demiol Drug Saf* 15:656–661 326
17. Iseki K, Miyasato F, Oura T et al (1994) An epidemiologic analysis
 327 of end-stage lupus nephritis. *Am J Kidney Dis* 23:547–554 328
18. Chiu YM, Lai CH (2010) Nationwide population-based epidemi-
 329 ologic study of systemic lupus erythematosus in Taiwan. *Lupus*
 330 19:1250–1255 331
19. Huang JL, Yao TC, See LC (2004) Prevalence of pediatric
 332 systemic lupus erythematosus and juvenile chronic arthritis in a
 333 Chinese population: a nation-wide prospective population-based
 334 study in Taiwan. *Clin Exp Rheumatol* 22:776–780 335
20. Wang TF, Lin HC (2008) Relationship between caseload volume
 336 and outcome for systemic lupus erythematosus treatment: the
 337 experience of Taiwan. *J Rheumatol* 35:1795–1800 338
21. Lindqvist KJ, Coleman RE, Osterland CK (1970) Autoantibodies
 339 in chronic pulmonary tuberculosis. *J Chronic Dis* 22:717–725 340
22. Singer JM, Plotz CM, Perlata FM et al (1962) The presence of anti-
 341 gamma globulin factors in sera of patients with active pulmonary
 342 tuberculosis. *Ann Intern Med* 56:545–552 343
23. Alarcon-Segovia D, Fishbein E (1975) Patterns of antinuclear
 344 antibodies and lupus-activating drugs. *J Rheumatol* 2:167–171 345
24. Sarzi-Puttini P, Atzeni F, Capsoni F et al (2005) Drug-induced
 346 lupus erythematosus. *Autoimmunity* 38:507–518 347
25. Shoenfeld Y, Vilner Y, Coates AR et al (1986) Monoclonal anti-
 348 tuberculosis antibodies react with DNA, and monoclonal anti-DNA
 349 autoantibodies react with *Mycobacterium tuberculosis*. *Clin Exp*
 350 *Immunol* 66:255–261 351
26. Correa PA, Gomez LM, Cadena J et al (2005) Autoimmunity and
 352 tuberculosis. Opposite association with TNF polymorphism.
 353 *J Rheumatol* 32:219–224 354